Latest 3 stories · newest Sep 29, 2026
Cartesian Therapeutics announced deep and durable responses in a five-patient retreatment study of Descartes-08 for myasthenia gravis. The data supports the company's Phase 3 AURORA program, with data expected in 1Q27.
Cartesian Therapeutics reported Q2 2026 financials, noting a cash balance of roughly $149 million and a non-dilutive credit facility set to extend runway. The company updated on its Descartes-08 pipeline trials in myasthenia gravis, myositis, and juvenile dermatomyositis with several data readouts e…
Cartesian Therapeutics announced a strategic licensing agreement with WestGene Biopharma to develop next-generation in vivo CAR-T treatments, combining WestGene's lipid nanoparticle platform with Cartesian's mRNA payload technology. A clinical trial is expected to begin in the second half of 2026 wi…
The same RNAC feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/RNAC/newsSTART FREE